Nanotechnology - a robust tool for fighting the challenges of drug resistance in non-small cell lung cancer

Area of Science:

• Oncology
• Nanomedicine
• Molecular Biology

Background:

• Genomic and proteomic analysis guides human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapies and monitors treatment.
• Acquired resistance to EGFR TKI therapy, driven by genetic aberrations, limits treatment options for cancer patients.
• Co-delivery of multiple agents targeting various signaling pathways is a strategy to overcome and prevent EGFR TKI resistance.

Purpose of the Study:

• To explore the potential of nanomedicine as a platform for overcoming challenges in combined EGFR TKI therapies.
• To address the pharmacokinetic differences and target delivery issues associated with co-administered therapeutic agents.
• To highlight the role of precision oncology and advanced nanocarrier design in improving cancer treatment efficacy.

Main Methods:

• Review of current strategies in genomic and proteomic analysis for EGFR TKI therapy selection.
• Discussion of resistance mechanisms and the rationale for combination therapies.
• Exploration of nanomedicine platforms and nanotools for simultaneous co-delivery of therapeutic agents.
• Emphasis on precision oncology for biomarker identification and tumor-homing agent optimization.
• Consideration of multifunctional, multistage nanocarrier design for tumor heterogeneity.

Main Results:

• Nanomedicine platforms and nanotools can overcome obstacles in simultaneous co-delivery of therapeutic agents.
• Multifunctional nanocarriers can address tumor heterogeneity, improve localization, and enhance intracellular internalization.
• Precision oncology approaches are crucial for optimizing targeted delivery and treatment outcomes.

Conclusions:

• Nanomedicine provides a viable strategy to overcome pharmacokinetic challenges and improve the efficacy of combined EGFR TKI therapies.
• Advanced nanocarrier design, coupled with precision oncology, holds significant promise for enhancing cancer treatment and preventing drug resistance.
• Further research in multifunctional nanocarriers is essential for advancing targeted cancer therapy.